# Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC

Source: [nature.com](https://www.nature.com/articles/s41571-026-01232-0) · 2026-11-06 · Medicine
Page: https://themorning.science/story/sacituzumab-tirumotecan-pembrolizumab-has-efficacy-in-pd-l1-negative-nsclc-2a537832428c8c0e

Nature Reviews Clinical Oncology, Published online: 06 November 2026; doi:10.1038/s41571-026-01232-0 Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC

## Coverage

- [Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC](https://www.nature.com/articles/s41571-026-01232-0) — nature.com, 2026-11-06

---

Brief generated by AI (–) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science